Cite
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data.
MLA
Gavriilaki, Eleni, et al. “Caplacizumab for Immune Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data.” Frontiers in Medicine, vol. 10, Oct. 2023, p. 1226114. EBSCOhost, https://doi.org/10.3389/fmed.2023.1226114.
APA
Gavriilaki, E., Nikolousis, E., Koravou, E.-E., Dimou-Besikli, S., Kartsios, C., Papakonstantinou, A., Mpanti, A., Pontikoglou, C., Kalpadaki, C., Bitsani, A., Tassi, I., Touloumenidou, T., Chatziconstantinou, T., Papathanasiou, M., Syrigou, A., Ztriva, E., Kaiafa, G., Mandala, E., Mellios, Z., … Sakellari, I. (2023). Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data. Frontiers in Medicine, 10, 1226114. https://doi.org/10.3389/fmed.2023.1226114
Chicago
Gavriilaki, Eleni, Emmanuel Nikolousis, Eudoxia-Evaggelia Koravou, Sotiria Dimou-Besikli, Charalampos Kartsios, Anna Papakonstantinou, Anastasia Mpanti, et al. 2023. “Caplacizumab for Immune Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data.” Frontiers in Medicine 10 (October): 1226114. doi:10.3389/fmed.2023.1226114.